Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)”

Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)”

Bibliographic Details
Main Authors:	Rosa De Miguel, David Rial-Crestelo, Lourdes Dominguez-Dominguez, Rocío Montejano, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Natalia Stella-Ascariz, Otilia Bisbal, Laura Bermejo-Plaza, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Mireia Santacreu-Guerrero, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	EBioMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396423000518

Similar Items

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
by: Rosa De Miguel, et al.
Published: (2020-05-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice
by: Sandra Medina-Moreno, et al.
Published: (2020-03-01)

Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
by: Ki Hyun Lee, et al.
Published: (2022-11-01)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
by: Lisi Deng, et al.
Published: (2022-01-01)

Assessment of treatment outcomes for HIV Positives transitioned from Tenofovir/Lamivudine/Efavirenz to Tenofovir/Lamivudine/Dolutegravir in a Nigerian Tertiary Hospital
by: Omobola Yetunde Ojo, et al.
Published: (2023-12-01)

Dolutegravir plus lamivudine for hiv treatment: Does the historical genotype really matter?
by: Andrea Giacomelli, et al.
Published: (2020-06-01)

Impact of tenofovir, lamivudine, and dolutegravir on liver function in HIV-positive individuals in Southern Nigeria
by: Odekunle Bola Odegbemi, et al.
Published: (2024-07-01)

The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review
by: Aprilianti S, et al.
Published: (2024-01-01)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
by: Carmen Hidalgo-Tenorio, et al.
Published: (2022-03-01)

Role of Dolutegravir/Lamivudine in the Management of Pregnant People Living with HIV-1: A Narrative Review
by: William R. Short, et al.
Published: (2024-12-01)

Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
by: Hernando Knobel, et al.
Published: (2023-12-01)

Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART
by: Ying Zhao, et al.
Published: (2024-04-01)

Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
by: Franco Maggiolo, et al.
Published: (2022-10-01)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
by: Alberto Borghetti, et al.
Published: (2019-01-01)

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe
by: Vinie Kouamou, et al.
Published: (2023-09-01)

Application of signal processing techniques for the spectroscopic analysis of dolutegravir and lamivudine: a comparative assessment and greenness appraisal
by: Reem M. Alnemari, et al.
Published: (2024-07-01)

Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV
by: Maria Mazzitelli, et al.
Published: (2023-08-01)

Switching to Dolutegravir + Lamivudine in a Highly Treatment-Experienced Patient Living with Human Immunodeficiency Virus Infection
by: Deniz GÖKENGİN, et al.
Published: (2022-12-01)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
by: Cruciani M, et al.
Published: (2015-02-01)

Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open-label, superiority trial in Copenhagen, Denmark
by: Jan Gerstoft, et al.
Published: (2023-08-01)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
by: Alfonso Cabello-Ubeda, et al.
Published: (2022-01-01)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.
by: Alfonso Cabello-Ubeda, et al.
Published: (2022-01-01)

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
by: Stefan Schneider, et al.
Published: (2024-04-01)

Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients
by: Francesca Lombardi, et al.
Published: (2019-05-01)

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain
by: Santiago Moreno Guillen, et al.
Published: (2017-09-01)

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
by: Hardik Chandasana, et al.
Published: (2024-07-01)

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form
by: Ramreddy Godela, et al.
Published: (2020-04-01)

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study
by: Roberta Gagliardini, et al.
Published: (2022-03-01)

QUANTITATION OF LAMIVUDINE BY UV SPECTROPHOTOMETRY
by: Y. A. Gonchikova, et al.
Published: (2017-07-01)

Lamivudine: fading into the mists of time
by: Jonggi Choi, et al.
Published: (2017-12-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
by: Inés Mendoza, et al.
Published: (2023-01-01)

Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults
by: Inés Mendoza, et al.
Published: (2023-01-01)

Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
by: Wang Li-Chun, et al.
Published: (2009-10-01)

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
by: Carlos Dueñas-Gutiérrez, et al.
Published: (2023-04-01)

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B
by: Chan Ho Park, et al.
Published: (2016-03-01)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
by: Suntisuklappon Busakorn, et al.
Published: (2010-10-01)

Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
by: Jeong Han Kim, et al.
Published: (2013-09-01)

AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
by: Zhao, Y, et al.
Published: (2021)

Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV
by: Zhenyan Wang, et al.
Published: (2024-11-01)